We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
Teladoc (TDOC - Free Report) reported $660.24 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 8%. EPS of -$0.35 for the same period compares to -$0.45 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $662.71 million, representing a surprise of -0.37%. The company delivered an EPS surprise of +5.41%, with the consensus EPS estimate being -$0.37.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teladoc performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
U.S. Integrated Care Members: 90.2 million compared to the 86.05 million average estimate based on five analysts.
BetterHelp Paying Users: 0.46 million compared to the 0.49 million average estimate based on five analysts.
Average Revenue Per U.S. Integrated Care Member: $1.41 versus the four-analyst average estimate of $1.44.
Chronic Care Enrollment: 1.12 million versus the four-analyst average estimate of 1.09 million.
Visits: 4,400,000 versus 2,567,396 estimated by two analysts on average.
Revenues by Segment- Teladoc Health Integrated Care: $374.42 million versus $370.86 million estimated by seven analysts on average.
Revenues by Segment- BetterHelp: $285.82 million versus $291.33 million estimated by seven analysts on average.
Revenues by Segment- BetterHelp- Other Wellness Services: $4.62 million versus $3.91 million estimated by four analysts on average.
Revenues by Segment- BetterHelp- Therapy Services: $281.20 million versus $288.28 million estimated by four analysts on average.
Adjusted EBITDA- BetterHelp: $25.95 million compared to the $33.47 million average estimate based on five analysts.
Adjusted EBITDA- Teladoc Health Integrated Care: $62.81 million compared to the $43.40 million average estimate based on five analysts.
Shares of Teladoc have returned -5.6% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Teladoc (TDOC - Free Report) reported $660.24 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 8%. EPS of -$0.35 for the same period compares to -$0.45 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $662.71 million, representing a surprise of -0.37%. The company delivered an EPS surprise of +5.41%, with the consensus EPS estimate being -$0.37.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Teladoc performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- U.S. Integrated Care Members: 90.2 million compared to the 86.05 million average estimate based on five analysts.
- BetterHelp Paying Users: 0.46 million compared to the 0.49 million average estimate based on five analysts.
- Average Revenue Per U.S. Integrated Care Member: $1.41 versus the four-analyst average estimate of $1.44.
- Chronic Care Enrollment: 1.12 million versus the four-analyst average estimate of 1.09 million.
- Visits: 4,400,000 versus 2,567,396 estimated by two analysts on average.
- Revenues by Segment- Teladoc Health Integrated Care: $374.42 million versus $370.86 million estimated by seven analysts on average.
- Revenues by Segment- BetterHelp: $285.82 million versus $291.33 million estimated by seven analysts on average.
- Revenues by Segment- BetterHelp- Other Wellness Services: $4.62 million versus $3.91 million estimated by four analysts on average.
- Revenues by Segment- BetterHelp- Therapy Services: $281.20 million versus $288.28 million estimated by four analysts on average.
- Adjusted EBITDA- BetterHelp: $25.95 million compared to the $33.47 million average estimate based on five analysts.
- Adjusted EBITDA- Teladoc Health Integrated Care: $62.81 million compared to the $43.40 million average estimate based on five analysts.
View all Key Company Metrics for Teladoc here>>>Shares of Teladoc have returned -5.6% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.